Article
A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Clinical lung cancer - 1 Jan 2018
Yang James Chih-Hsin, Mok Tony, Han Baohui, Orlando Mauro, Puri Tarun, Park Keunchil
Abstract excerpt
Pemetrexed is a standard first-line treatment for advanced nonsquamous non-small-cell lung cancer (NSCLC), and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a standard first-line treatment for advanced nonsquamous NSCLC with activating EGFR mutations. Pemetrexed and EGFR TKIs have different mechanisms of action and minimally overlapping toxicity profiles; therefore, it is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.